Undifferentiated Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
Conditions: Nasopharyngeal Nonkeratinizing Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage III Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Undifferentiated CarcinomaInterventions: Other: Laboratory Biomarker Analysis; Biological: NivolumabSponsor: National Cancer Institute (NCI)Not yet recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2015 Category: Research Source Type: clinical trials
Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Conditions: Metastatic Anaplastic/Undifferentiated Thyroid Cancer; Locally Advanced Anaplastic/Undifferentiated Thyroid CancerIntervention: Drug: CeritinibSponsors: University of Texas Southwestern Medical Center; NovartisNot yet recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2014 Category: Research Source Type: clinical trials
Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Conditions: Metastatic Anaplastic/Undifferentiated Thyroid Cancer; Locally Advanced Anaplastic/Undifferentiated Thyroid CancerIntervention: Drug: CeritinibSponsors: University of Texas Southwestern Medical Center; NovartisNot yet recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2014 Category: Research Source Type: clinical trials